138 related articles for article (PubMed ID: 22626577)
1. Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study.
Hirayama A; Torimoto K; Mastusita C; Okamoto N; Morikawa M; Tanaka N; Fujimoto K; Yoshida K; Hirao Y; Kurumatani N
Urology; 2012 Jul; 80(1):71-6. PubMed ID: 22626577
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of factors influencing the natural history of nocturia in elderly subjects: results of the Fujiwara-kyo Study.
Hirayama A; Torimoto K; Mastusita C; Okamoto N; Morikawa M; Tanaka N; Yoshida K; Fujimoto K; Hirao Y; Kurumatani N
J Urol; 2013 Mar; 189(3):980-6. PubMed ID: 23036982
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for overactive bladder in the elderly population: a community-based study with face-to-face interview.
Ikeda Y; Nakagawa H; Ohmori-Matsuda K; Hozawa A; Masamune Y; Nishino Y; Kuriyama S; Ohnuma T; Tsuji I; Arai Y
Int J Urol; 2011 Mar; 18(3):212-8. PubMed ID: 21198945
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes.
Liu RT; Chung MS; Lee WC; Chang SW; Huang ST; Yang KD; Chancellor MB; Chuang YC
Urology; 2011 Nov; 78(5):1040-5. PubMed ID: 21958505
[TBL] [Abstract][Full Text] [Related]
5. High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms.
Chiu AF; Liao CH; Wang CC; Wang JH; Tsai CH; Kuo HC
Urology; 2012 Feb; 79(2):260-5. PubMed ID: 22137542
[TBL] [Abstract][Full Text] [Related]
6. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
7. The association between the self-perception period of overactive bladder symptoms and overactive bladder symptom scores in a non-treated population and related sociodemographic and lifestyle factors.
Kim JH; Ham BK; Shim SR; Lee WJ; Kim HJ; Kwon SS; Bae JH
Int J Clin Pract; 2013 Aug; 67(8):795-800. PubMed ID: 23869680
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
[TBL] [Abstract][Full Text] [Related]
9. Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the Overactive Bladder Symptom Score.
Ohgaki K; Horiuchi K; Kondo Y
Urology; 2012 Jun; 79(6):1372-8. PubMed ID: 22656415
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
[TBL] [Abstract][Full Text] [Related]
11. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women.
Zhang W; Song Y; He X; Huang H; Xu B; Song J
Neurourol Urodyn; 2006; 25(7):717-21. PubMed ID: 16944449
[TBL] [Abstract][Full Text] [Related]
14. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
[TBL] [Abstract][Full Text] [Related]
15. Health-related consequences of overactive bladder.
Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.
Irwin DE; Milsom I; Kopp Z; Abrams P; Artibani W; Herschorn S
Eur Urol; 2009 Jul; 56(1):14-20. PubMed ID: 19278775
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome in female patients with overactive bladder.
Uzun H; Zorba OÜ
Urology; 2012 Jan; 79(1):72-5. PubMed ID: 22014972
[TBL] [Abstract][Full Text] [Related]
19. Reliability and validity of the Overactive Bladder Symptom Score in Spanish (OABSS-S).
Weinberg AC; Brandeis GH; Bruyere J; Tsui JF; Weiss JP; Rutman MP; Blaivas JG
Neurourol Urodyn; 2012 Jun; 31(5):664-8. PubMed ID: 22488591
[TBL] [Abstract][Full Text] [Related]
20. Overactive bladder: prevalence and implications in Brazil.
Teloken C; Caraver F; Weber FA; Teloken PE; Moraes JF; Sogari PR; Graziottin TM
Eur Urol; 2006 Jun; 49(6):1087-92. PubMed ID: 16497431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
